NeoGenomics (NASDAQ:NEO) Given Buy Rating at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of NeoGenomics (NASDAQ:NEO – Free Report) in a report published on Tuesday morning, Benzinga reports. Needham & Company LLC currently has a $21.00 price target on the medical research company’s stock. Several other equities research analysts also recently issued reports on the stock. William Blair […]

Leave a Reply

Your email address will not be published.

Previous post EverCommerce (NASDAQ:EVCM) Price Target Cut to $12.00 by Analysts at Royal Bank of Canada
Next post Evercore ISI Initiates Coverage on ON (NYSE:ONON)